Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
103 hedge funds and large institutions have $707M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 17 reducing their positions, and 7 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
194% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 17
96% more capital invested
Capital invested by funds: $362M → $707M (+$345M)
21% more funds holding
Funds holding: 85 → 103 (+18)
2% more call options, than puts
Call options by funds: $47K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$25.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.3M |
| 3 |
VA
VR Adviser
New York
|
+$18.3M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$17.3M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.47M |
| 2 |
AC
Armistice Capital
New York
|
-$2.68M |
| 3 |
Renaissance Technologies
New York
|
-$2.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.99M |
| 5 |
Two Sigma Investments
New York
|
-$1.61M |
KDNY Hedge Fund Activity: Q4 2021 in Review
103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2021, worth a combined $707M — up 96% from $362M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KDNY positions and 7 closed out — a net gain of 18 holders — while 50 added to existing stakes and 17 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $25.6M. The largest seller was Millennium Management, cutting an estimated $4.47M.
- 103 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2021, up from 85 in Q3 2021.
- Funds reported $707M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2021, up 96% quarter-over-quarter.
- 25 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of +18 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2021 was BVF Inc, an estimated $25.6M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $4.47M sold.
Based on aggregated 13F filings for Q4 2021.